← All trials
NCT05468060
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2020
- Primary completion
- Dec 12, 2020
- Completion date
- Dec 12, 2020
- First posted
- Jul 21, 2022
- Last posted
- Jul 21, 2022
- Enrollment
- 80
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang Palo Alto Pharmaceuticals, Inc.Lead sponsor
- Xuzhou Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.